Fed Regist. 2004 Aug 9;69(152):48146-8.
The Food and Drug Administration (FDA) is classifying silicone sheeting intended for use in the management of closed hyperproliferative (hypertrophic and keloid) scars into class I (general controls). As a class I device, the device will be exempt from premarket notification requirements. This action is taken under the Federal Food, Drug, and Cosmetic Act (the act), as amended by the Medical Device Amendments of 1976 (the 1976 amendments), the Safe Medical Devices Act of 1990 (the SMDA), the Food and Drug Administration Modernization Act of 1997 (FDAMA), and the Medical Devices User Fee Modernization Act of 2002 (MDUFMA).
美国食品药品监督管理局(FDA)正在将用于治疗闭合性增生性(肥厚性和瘢痕疙瘩性)瘢痕的硅胶片归类为I类(一般控制)医疗器械。作为I类器械,该产品将免于上市前通知要求。此行动是依据经1976年《医疗器械修正案》(1976年修正案)、1990年《安全医疗器械法案》(SMDA)、1997年《食品药品管理局现代化法案》(FDAMA)以及2002年《医疗器械用户收费现代化法案》(MDUFMA)修订的《联邦食品、药品和化妆品法案》(该法案)采取的。